Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis

Area of Science:

• Cardiovascular disease research
• Rheumatology
• Lipid metabolism

Background:

• Patients with rheumatoid arthritis (RA) face elevated cardiovascular (CV) risk, not fully explained by standard cholesterol levels.
• Cholesterol efflux capacity (CEC) of high-density lipoprotein (HDL) may be a more accurate CV risk predictor than HDL concentration.
• This study investigated if CEC is impaired in RA and linked to coronary atherosclerosis.

Purpose of the Study:

• To assess HDL's cholesterol efflux capacity in RA patients compared to controls.
• To determine the association between CEC and coronary artery calcification in RA.
• To explore correlations between CEC and RA disease activity markers.

Main Methods:

• Measured net cholesterol efflux capacity and coronary artery calcium score in 134 RA patients and 76 controls.
• Analyzed the relationship between CEC, coronary artery calcium score, and clinical variables in RA patients.
• Adjusted for age, sex, race, Framingham risk score, and diabetes status.

Main Results:

• Net cholesterol efflux capacity was comparable between RA patients and control subjects (34% vs. 35%).
• No significant association was found between higher CEC and reduced coronary artery calcium score in RA patients.
• CEC did not correlate significantly with RA disease activity, C-reactive protein, or insulin resistance.

Conclusions:

• Net cholesterol efflux capacity is not significantly altered in RA patients with well-controlled disease.
• CEC is not significantly associated with coronary artery calcification in this RA cohort.
• HDL cholesterol efflux capacity may not be the primary driver of increased CV risk in RA.